439 related articles for article (PubMed ID: 29551594)
1. Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.
Nakamura K; Kassem S; Cleynen A; Chrétien ML; Guillerey C; Putz EM; Bald T; Förster I; Vuckovic S; Hill GR; Masters SL; Chesi M; Bergsagel PL; Avet-Loiseau H; Martinet L; Smyth MJ
Cancer Cell; 2018 Apr; 33(4):634-648.e5. PubMed ID: 29551594
[TBL] [Abstract][Full Text] [Related]
2. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
3. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
Front Immunol; 2018; 9():1179. PubMed ID: 29896199
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation.
Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y
Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371
[TBL] [Abstract][Full Text] [Related]
6. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
7. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
8. Estrogen promotes multiple myeloma through enhancing the immunosuppressive activity of MDSC.
Ozerova M; Nefedova Y
Leuk Lymphoma; 2019 Jun; 60(6):1557-1562. PubMed ID: 30601091
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
10. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes.
Han D; Tao J; Fu R; Shao Z
Innate Immun; 2020 Nov; 26(8):703-715. PubMed ID: 33050756
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow transplantation generates T cell-dependent control of myeloma in mice.
Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR
J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
[TBL] [Abstract][Full Text] [Related]
14. Hepatic Stellate Cells Enhance Liver Cancer Progression by Inducing Myeloid-Derived Suppressor Cells through Interleukin-6 Signaling.
Hsieh CC; Hung CH; Chiang M; Tsai YC; He JT
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614930
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Zheng Y; Tian X; Wang T; Xia X; Cao F; Tian J; Xu P; Ma J; Xu H; Wang S
Mol Cancer; 2019 Mar; 18(1):61. PubMed ID: 30925926
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma and the Immune Microenvironment.
Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
[TBL] [Abstract][Full Text] [Related]
17. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy.
Yin Z; Li C; Wang J; Xue L
Int J Cancer; 2019 Mar; 144(5):933-946. PubMed ID: 29992569
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives.
Safari E; Ghorghanlu S; Ahmadi-Khiavi H; Mehranfar S; Rezaei R; Motallebnezhad M
J Cell Physiol; 2019 Jul; 234(7):9966-9981. PubMed ID: 30537008
[TBL] [Abstract][Full Text] [Related]
20. Suppression of T cells by myeloid-derived suppressor cells in cancer.
Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
